Susquehanna Fundamental Investments LLC Makes New Investment in Verastem, Inc. (NASDAQ:VSTM)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 63,411 shares of the biopharmaceutical company's stock, valued at approximately $328,000. Susquehanna Fundamental Investments LLC owned about 0.14% of Verastem at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Verastem by 51.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 1,698 shares in the last quarter. Voya Investment Management LLC acquired a new stake in Verastem in the 4th quarter worth about $59,000. Invesco Ltd. boosted its holdings in Verastem by 18.4% in the 4th quarter. Invesco Ltd. now owns 14,680 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 2,281 shares during the period. JPMorgan Chase & Co. grew its position in shares of Verastem by 55.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 6,016 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Verastem by 41.3% during the fourth quarter. Wells Fargo & Company MN now owns 20,571 shares of the biopharmaceutical company's stock worth $106,000 after purchasing an additional 6,012 shares during the period. 88.37% of the stock is currently owned by institutional investors.

Verastem Price Performance

NASDAQ:VSTM traded up $0.23 on Friday, hitting $7.17. The company had a trading volume of 2,621,063 shares, compared to its average volume of 1,071,573. Verastem, Inc. has a 52 week low of $2.10 and a 52 week high of $13.52. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. The stock has a market capitalization of $369.18 million, a price-to-earnings ratio of -2.25 and a beta of 0.85. The firm has a 50 day moving average of $6.36 and a two-hundred day moving average of $5.46.

Verastem (NASDAQ:VSTM - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.57). On average, research analysts anticipate that Verastem, Inc. will post -3.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on VSTM shares. Guggenheim boosted their price target on Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Monday, March 24th. Royal Bank of Canada cut their target price on Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday, March 21st. StockNews.com cut Verastem from a "hold" rating to a "sell" rating in a research report on Friday, April 18th. HC Wainwright upped their price objective on shares of Verastem from $10.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Mizuho reduced their price objective on shares of Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $14.33.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.